3rd Annual MarketsandMarkets

Real-World Data, Life Sciences Analytics and Market Access Virtual Conference ( Time Zone - EASTERN STANDARD TIME (EST)

October 22nd - 23rd, 2020

MarketsandMarkets is proud to announce the 3rd Annual Real-World Data, Life Sciences Analytics and Market Access – Virtual Conference to be held on October 22nd -23rd, 2020.

While the 2nd annual Congress had discussions on accelerating the adoption of Real-world Evidence within the industry while understanding the capabilities of newer technologies for evidence generation, the 3rd Annual will focus on how the insights derived from real world data, as well as acknowledgment of the effect the insights can have on improving decision making and patient consideration both internally and by regulators, doctors, and payers.

Our aim for the 3rd Annual Real-World Data, Life Sciences Analytics and Market Access – Virtual Conference is to unite all stakeholders in a virtual room during these remarkable times to see how to use conventional informational indexes and layer that in with innovative analytical techniques and new working models.

The virtual conference will also hold discussion on the impact due to COVID-19 in RWD space- Identifying and overcoming those challenges efficiently

WHAT TO EXPECT

  • Progression on uses of Real-World Data across the ecosystem
  • Global regulatory perspective on Real-World Evidence Guidance- FDA & EMA
  • Applications of Artificial Intelligence & Blockchain for Real-World Data Analysis
  • Market Access and Pricing
  • COVID-19 impact- Identifying and overcoming challenges in Real-World Evidence space

From pharmaceutical and Biopharmaceutical companies-

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists, Bio-Statisticians, Epidemiologist, within the following departments

  • Real-World Evidence
  • Health Economics & Outcomes Research
  • Patient Access
  • Value Access
  • Clinical Operations
  • Clinical Development
  • Center for Observational and Real-World Evidence  

 

  • Understand the impact of innovative real-world evidence partnerships for better data
  • To explore the capabilities of using Artificial Intelligence & Machine Learning for better Data Analysis
  • Learn about global regulatory perspective on Real-World Evidence Guidance
  • Learn about best practices for the commercial structure of drugs, from development to market access strategy
  • Opportunity to network and exchange scientific knowledge with expert speakers from leading manufacturers, global regulators, and solution providers

CONFERENCE AGENDA

Registration

08:30 - 09:00

Welcome note from MarketsandMarkets

09:00 - 09:05

PROGRESSION ON USES OF REAL-WORLD DATA ACROSS THE ECOSYSTEM

Opening Remarks from the Chairman

Angela Ibald-Mulli

Angela Ibald-Mulli , Head, Medical Evidence Generation Primary Care , Sanofi

09:05 - 09:10

Keynote Presentation: Building and scaling organizational RWE capabilities to maximize return

Charles Makin

Charles Makin , Global Head of HEOR and RWE, Global Head of Pipeline Value & Access, Biogen

09:10 - 09:40

Multiple sclerosis outcomes database

Guru Rao KS

Guru Rao KS, Senior Vice President, Molecular Connections Private Limited

09:40 - 10:10

Real-World Evidence in Drug Development: The FDA Experience

Nneka Onwudiwe

Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, FOOD AND DRUG ADMINISTRATION

10:10 - 10:40

Using Real World Clinical NGS Data for Precision Oncology

Sheryl Krevsky Elkin

Sheryl Krevsky Elkin , Chief Scientific Officer , QIAGEN Digital Insights

10:40 - 11:15

One-to-One Networking Meetings | Networking break

11:15 - 11:35

ARTIFICIAL INTELLIGENCE, BLOCKCHAIN AND BIG DATA: GAMECHANGER IN REAL-WORLD EVIDENCE GENERATION

Advanced real-world evidence as a competitive advantage

Dan Riskin

Dan Riskin , Founder and CEO, Verantos

11:35 - 12:05

Considerations and challenges around AI enabled clinical decision support

Angela Ibald-Mulli

Angela Ibald-Mulli , Head, Medical Evidence Generation Primary Care , Sanofi

12:05 - 12:35

BigData & Artificial Intelligence: separating facts from fiction

Ignacio Hernandez Medrano

Ignacio Hernandez Medrano, Founder, Savana Medica

12:35 - 13:05

Challenges and opportunities on generating “regulatory grade” Real World Evidence

David Miller

David Miller, Executive Director, Head of RWE- Patient Safety, Sarepta Therapeutics, USA

13:05 - 13:35

Closing remarks from the Chairperson

13:35 - 13:40

One-to-One Networking Meetings | Networking break

13:40 - 14:30

IMPLICATIONS OF MARKET ACCESS AND PATIENT ACCESS TO MEASURE IMPACT

Opening Remarks from the Chairman

Tao Fan

Tao Fan , Senior Director, US HEOR US Medical Office , Takeda Pharmaceuticals

09:05 - 09:10

Market Access & Pricing / What do you need to consider for a success drug launch?

Raymond Frost

Raymond Frost, Vice President, Market Access & Health Policy, Melinta

09:10 - 09:40

Innovative Payment Models: Practical Learnings from the US Launch of the First Gene Therapy for a Genetic Disease

Jay Newman

Jay Newman, Head of US Commercial, Spark Therapeutics

09:40 - 10:10

Integrating Real-World Datasets to Understand Socio-Economic Disparities in Access to Healthcare

Tom Haskell

Tom Haskell, Managing Director, RWExperts LLC

10:10 - 10:40

Generating Real World Evidence in Medical Affairs: Challenges and New Opportunities

Andrei Pikalov

Andrei Pikalov, Vice President, Head of Global Medical Affairs, Sunovion Pharmaceuticals

10:40 - 11:15

One-to-One Networking Meetings | Networking break

11:15 - 11:35

GLOBAL REGULATORY PERSPECTIVE ON REAL-WORLD EVIDENCE GUIDANCE

RWE for regulatory and HTA decision-making: latest precedent and what’s ahead

Ashley Jaksa

Ashley Jaksa, VP of Science , Aetion

11:35 - 11:50

Panel discussion- Assessing the upcoming changes in the regulatory landscape in terms of Real-World Data- FDA, EMA, PMDA & industry perspective

11:50 - 12:35

Comprehensive real-world evidence generation strategy to support reimbursement and market access

Eliza Kruger

Eliza Kruger, Associate Director, Global HEOR, Ultragenyx Pharmaceuticals

12:35 - 13:05

Closing remarks from the Chairperson

13:05 - 13:10

One-to-One Networking Meetings | Networking break

13:10 - 14:30

Registration

08:30 - 08:55

Welcome note from MarketsandMarkets

08:55 - 09:00

Opening Remarks from the Chairman

Eliza Kruger

Eliza Kruger, Associate Director, Global HEOR, Ultragenyx Pharmaceuticals

09:00 - 09:05

NEW FORMS OF REAL-WORLD DATA

What are Registries for Rare Diseases?

Rafael Ioschpe

Rafael Ioschpe, Associate Director, RWE Strategic Operations Lead, Rare Disease, , Sanofi Genzyme

09:05 - 09:35

Impact of COVID-19 on the generation and use of real-world data and evidence

Nirosha Lederer

Nirosha Lederer , Managing Associate, Real World Evidence, Duke Margolis Center for Health Policy, Duke University

09:35 - 10:05

Best Practices in Long-Term Safety Follow-Up Studies – Using technology to ensure safety and lighten site and patient burden

Noolie Gregory

Noolie Gregory, Executive Director, Client Engagement Solutions, Real World Late Phase, Syneos Health

10:05 - 10:35

Generating Real-World Evidence For Stakeholders Including Physicians, Patients, and Payers

Shaum Kabadi

Shaum Kabadi, Director of Global Real-World Evidence in Oncology, AstraZeneca

10:35 - 11:00

Causal Inference Methods for Real World Evidence: a Case Study of a Target Trial Emulation

Xabier Garcia de Albeniz Martinez

Xabier Garcia de Albeniz Martinez , Director, Epidemiology , RTI Health Solutions

11:00 - 11:30

One-to-One Networking Meetings | Networking break

11:30 - 11:50

BREAKTHROUGH TO EXCELLENT DATA EVALUATION

Real-World Data Hubs - technology platforms to enable clinical outcome & RWE collaborations between hospitals and Life Sciences Industry

Georges De Feu

Georges De Feu, Founder & CEO, Lynxcare

11:50 - 12:20

Real World Data in a pandemic: Making sense of EHR data for COVID-19

12:20 - 12:50

Closing remarks from the Chairman

12:50 - 12:55

SPEAKERS

Charles Makin

Charles Makin

Global Head of HEOR and RWE, Global Head of Pipeline Value & Access, Biogen

Nneka Onwudiwe

Nneka Onwudiwe

Former PRO/PE Regulatory Review Officer, FOOD AND DRUG ADMINISTRATION

Vic Spain

Vic Spain

Senior Real World Data Scientist , Genentech

David Miller

David Miller

Executive Director, Head of RWE- Patient Safety, Sarepta Therapeutics, USA

Nirosha Lederer

Nirosha Lederer

Managing Associate, Real World Evidence, Duke Margolis Center for Health Policy, Duke University

Alexander Cole

Alexander Cole

Executive Director, Global Head Epidemiology, Alexion Pharmaceuticals

Raymond Frost

Raymond Frost

Vice President, Market Access & Health Policy, Melinta

Eliza Kruger

Eliza Kruger

Associate Director, Global HEOR, Ultragenyx Pharmaceuticals

Rafael Ioschpe

Rafael Ioschpe

Associate Director, RWE Strategic Operations Lead, Rare Disease, , Sanofi Genzyme

Jay Newman

Jay Newman

Head of US Commercial, Spark Therapeutics

Devika Chawla

Devika Chawla

Senior Data Scientist, Real World Data, Personalized Healthcare, Product Development, Genentech

Shemra Rizzo

Shemra Rizzo

Senior Data Scientist, Data Science Analytics, Personalized Healthcare, Product Development , Genentech

Sheryl Krevsky Elkin

Sheryl Krevsky Elkin

Chief Scientific Officer , QIAGEN Digital Insights

Dan Riskin

Dan Riskin

Founder and CEO, Verantos

Susan Fish

Susan Fish

Associate Director, Strategic Evidence Integration and Collaborations US Medical Affairs Hematology,, Bristol-Myers Squibb

Xabier Garcia de Albeniz Martinez

Xabier Garcia de Albeniz Martinez

Director, Epidemiology , RTI Health Solutions

Tao Fan

Tao Fan

Senior Director, US HEOR US Medical Office , Takeda Pharmaceuticals

Angela Ibald-Mulli

Angela Ibald-Mulli

Head, Medical Evidence Generation Primary Care , Sanofi

Guru Rao KS

Guru Rao KS

Senior Vice President, Molecular Connections Private Limited

Lynn Donald

Lynn Donald

Senior Project Director, Oncology, Novel and Emerging Therapies , Syneos Health

Tom Haskell

Tom Haskell

Managing Director, RWExperts LLC

Noolie Gregory

Noolie Gregory

Executive Director, Client Engagement Solutions, Real World Late Phase, Syneos Health

Mike D'Ambrosio

Mike D'Ambrosio

Senior Project Director, Real World Late Phase, Syneos Health

Shaum Kabadi

Shaum Kabadi

Director of Global Real-World Evidence in Oncology, AstraZeneca

Ignacio Hernandez Medrano

Ignacio Hernandez Medrano

Founder, Savana Medica

Georges De Feu

Georges De Feu

Founder & CEO, Lynxcare

Andrei Pikalov

Andrei Pikalov

Vice President, Head of Global Medical Affairs, Sunovion Pharmaceuticals

Ashley Jaksa

Ashley Jaksa

VP of Science , Aetion

SPONSORS

Adelphi Real World
Picnic Health
OPEN Health
Premier Inc.
QIAGEN
Verantos
Syneos Health
Molecular Connections
Kantar
Savana
Aetion
RTI Health Solutions
LynxCare